Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

NCT01907607 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Institut Bergonié